Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David J. Kilian"'
Autor:
Axel Hoos, Sara Brett, Michael Conner, Lyuben Tsvetkov, Meixia Bi, Christopher B. Hopson, Sabyasachi Bhattacharya, Sapna Yadavilli, Christopher M. Traini, Wendy S. Halsey, James F. Smothers, Heather Kaczynski, Nicholas J. Vitali, David J. Figueroa, Laura M. Seestaller-Wehr, Hui Zhou, Niranjan Yanamandra, William G. Benson, Roopa Srinivasan, Jun Yu, Junping Jing, Yuliya V. Katlinskaya, Ashleigh Hahn, Ashley M. Hughes, Tae Lee, Hong Shi, David J. Kilian
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 11, p e0206223 (2018)
PLoS ONE, Vol 13, Iss 11, p e0206223 (2018)
Mouse syngeneic tumor models are widely used tools to demonstrate activity of novel anti-cancer immunotherapies. Despite their widespread use, a comprehensive view of their tumor-immune compositions and their relevance to human tumors has only begun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::337e23090326878ed2bfbc37bebde83b
https://pubmed.ncbi.nlm.nih.gov/30388137
https://pubmed.ncbi.nlm.nih.gov/30388137
Autor:
Ruth J. Mayer, Michael Salmon, Miriam Burman, Donald C. Carpenter, Jakob Busch-Petersen, John Yonchuk, David J. Kilian, James J. Foley, Gerald E. Hunsberger, Ruth Tal-Singer
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 362(2)
CXC chemokine receptor 2 (CXCR2) is a key receptor in the chemotaxis of neutrophils to sites of inflammation. The studies reported here describe the pharmacological characterization of danirixin, a CXCR2 antagonist in the diaryl urea chemical class.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653c1590be6e82e88b8bc4de3ebcf433
https://pubmed.ncbi.nlm.nih.gov/28611093
https://pubmed.ncbi.nlm.nih.gov/28611093
Autor:
Michael Adam, Niranjan Yanamandra, M. Phillip DeYoung, Christina Blackwell, Ashleigh Hahn, Shu-Yun Zhang, David J. Kilian, Yao-Bin Liu, Roopa Srinivasan, Christopher B. Hopson, Sapna Yadavilli, Yuliya V. Katlinskaya, Tianqian Zhang, Axel Hoos, Sabyasachi Bhattacharya, Hong Shi, Patrick A. Mayes, Meixia Bi, Laura M. Seestaller-Wehr
Publikováno v:
Cancer Research. 77:1637-1637
Inducible T-cell costimulator (ICOS) is a costimulatory receptor that is upregulated on activated CD4 and CD8 T cells and plays an important role in T cell survival, differentiation, regulation of memory and regulatory T cell pools and humoral respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::284f3adead674f9a31bde4d9dd48cd46
https://doi.org/10.1158/1538-7445.am2017-1637
https://doi.org/10.1158/1538-7445.am2017-1637
Autor:
James F. Smothers, Christopher B. Hopson, L. Seestaller Wehr, Niranjan Yanamandra, Axel Hoos, Hong Shi, Elaine M. Paul, Sabyasachi Bhattacharya, Paul Bojczuk, Peter J. Morley, David J. Kilian, Heather Jackson, Michael Adam, Meixia Bi, Junping Jing, Ashleigh Hahn, Roopa Srinivasan
Publikováno v:
Annals of Oncology. 29:viii424-viii425
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40dfc9663e8bad48cdf1eb20345aa421
https://doi.org/10.1093/annonc/mdy288.065
https://doi.org/10.1093/annonc/mdy288.065
Autor:
Douglas W. P. Hay, Raveglia Luca Francesco, Don E. Griswold, Brian Bush, Punam Sandhu, Henry M. Sarau, Dulcie B. Schmidt, Giuseppe Giardina, James J. Foley, Mario Grugni, Jeffrey J. Legos, Lenox D. Martin, Dave Lundberg, Charles J. Kotzer, David J. Kilian, William Potts, Frank C. Barone, Mark A. Luttmann, David C. Underwood
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 300:314-323
In this report the in vitro and in vivo pharmacological and pharmacokinetic profile of (-)-(S)-N-(alpha-ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide (SB 235375), a low central nervous system (CNS)-penetrant, human neurokinin-3 (NK-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac96267867eb1bee66448443b306e2ab
https://doi.org/10.1124/jpet.300.1.314
https://doi.org/10.1124/jpet.300.1.314
Autor:
Jennifer Greer, Christopher B. Hopson, Tim Lofton, Junping Jing, David J. Kilian, Laura Bover, Carlo Toniatti, Amin Al-Shami, Ignacio I. Wistuba, Roopa Srinivasan, Peter J. Morley, Paul Bojczuk, Sara Brett, Kui Voo, Heather Jackson, Axel Hoos, Niranjan Yanamandra, Sabyasachi Bhattacharya, Ningping Feng, Kevin French, Mili Mandal
Publikováno v:
Cancer Research. 76:4864-4864
Introduction: GSK3174998, a humanized IgG1 agonistic anti-OX40 monoclonal antibody (mAb) identified in collaboration between GSK and MDACC is currently in Phase I clinical development. Critical for the development of more effective cancer immunothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbf7b9cb926a8e0efbb3a0202cca5f8d
https://doi.org/10.1158/1538-7445.am2016-4864
https://doi.org/10.1158/1538-7445.am2016-4864
Autor:
Nicholas J. Vitali, Axel Hoos, Shu-Yun Zhang, Ashleigh Hahn, Sabyasachi Bhattacharya, Roopa Srinivasan, Niranjan Yanamandra, Sapna Yadavilli, Michael Adam, Yufeng Li, Laura M. Seestaller-Wehr, Meixia Bi, David J. Kilian
Publikováno v:
Cancer Immunology Research. 4:A149-A149
The explosion of research in the cancer immunotherapy field has led to a quest for better animal models to validate and develop various immunotherapies. Syngeneic mouse tumor models are one of the best options currently available to select cancers wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d98cde22f0d58dcfc066777ede0aa31
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a149
https://doi.org/10.1158/2326-6074.cricimteatiaacr15-a149